...
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use.
【24h】

A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use.

机译:一例继发于波马来胺和左氧氟沙星的结晶性肾病致急性肾脏损伤。

获取原文
获取原文并翻译 | 示例
           

摘要

Pomalidomide is an analog of thalidomide with immunomodulatory, anti-angiogenic, and anti-neoplastic activity indicated for the treatment of multiple myeloma refractory to at least two prior therapies. The incidence for renal failure was <5% in a single phase II study of pomalidomide and dexamethasone in patients with multiple myeloma that failed both lenalidomide and bortezomib therapy. We report a case suggesting crystal nephropathy as the mechanism for acute kidney injury in pomalidomide and fluoroquinolone use.
机译:泊马利度胺是沙利度胺的类似物,具有免疫调节,抗血管生成和抗肿瘤活性,可用于治疗至少两种先前治疗难以治愈的多发性骨髓瘤。在雷那度胺和硼替佐米治疗均无效的多发性骨髓瘤患者中,波马利度胺和地塞米松的II期单项II期研究表明,肾衰竭的发生率<5%。我们报道了一个病例,该病例提示结晶性肾病是pomalidomide和氟喹诺酮类药物急性肾损伤的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号